In addition, in the study of MAFLD (NAFLD) characterized by hepatic steatosis and inflammation, Sal B can also inhibit the migration and release of high mobility group protein 1 (HMGB1) by upregulating SIRT1 expression (Zeng et al., 2015). Here, HMGB1 is linked to metabolic dysfunction-associated steatotic liver disease.